With the comprehensive care programme, we support the Ministry of Health (MoH) in its rollout of protocols reflecting global best practices, as well as introduce healthcare innovations, and promote shorter course TB treatment regimens using new and repurposed drugs.
We have also implemented the TB PRACTECAL clinical trial. This is the first-ever multi-country, randomised, controlled clinical trial, aiming to demonstrate the safety and efficacy of a six-month, all oral treatment regimen for drug-resistant TB. We are now working with the World Health Organization to promote the new regimen as the international standard of care for drug-resistant TB patients.
In the capital, Tashkent, we provide support for the diagnosis and treatment of people living with HIV and co-infections. In 2021, we also launched a mobile laboratory to support the diagnosis of HIV and co-infections among vulnerable people.
Our teams also support the MoH in its efforts to develop the public healthcare system.
Our activities in 2021 in Uzbekistan
Data and information from the International Activity Report 2021.
In March 2021, we completed enrolment of patients in the Uzbekistan branch of the TB PRACTECAL clinical trial nine months ahead of schedule, since it had already successfully demonstrated that its all-oral six-month treatment regimen is safer and more effective at treating rifampicin-resistant TB than the current international standard of care.
In view of this early success, the trial teams in Nukus and Tashkent started preparations to support the roll-out of all-oral six-month regimens across the country under the conditions of operational research. In addition, we continued to support the national TB programme in Nukus with technical expertise, laboratory diagnostics and medication for patients with drug-resistant TB in Karakalpakstan.
In Tashkent, we scaled up HIV testing and treatment through the ‘one-stop shop’ model of care, which enables HIV patients to receive screening for various infectious diseases in one location. Towards the end of the year, we conducted a multi-regional training programme for physicians to increase their capacity to deliver care through this model, and launched a mobile laboratory to improve access to testing for HIV, hepatitis C and other sexually transmitted infections for marginalised groups. We also supported treatment and drug supply in Tashkent’s Hospital No 5 for HIV patients, including those with co-infections.